Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results BioSpaceShares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) BioSpace Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimismNext: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
